Meningioma clinical trials
34 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Cabozantinib for Patients With Recurrent or Progressive Meningioma
- A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
- Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
- A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
- Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NEO100 and High-Grade Meningioma
- Abemaciclib in Newly Diagnosed Meningioma Patients
- Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
- Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
- Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
- Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
- In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
- Evaluation of the CONVIVO System
- 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
- Cognitive Status After Removal of Skull Base Meningioma
- Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma
- Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
- Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- Natural History Study of Patients With Neurofibromatosis Type 2
- Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
- HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
- Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
- ICG Angiogram as a Predictor of Postoperative Visual Function After EEA Surgery
- Long-Term Longitudinal QoL in Patients Undergoing EEA
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Meningioma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.